Sign In
Buy DGX
$196.12
+2.45 (+1.27%)
At Close: Jun 04, 2026
OPKO Health (OPK) Stock Gains 2.1% Despite Q2 Earnings Miss
01:14pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.
NuVasive (NUVA) Q2 Earnings Miss Estimates, Revenues Beat
04:29pm, Monday, 08'th Aug 2022 Zacks Investment Research
NuVasive's (NUVA) Q2 revenues outpaced the consensus mark with strong sales across U.S. Spinal Hardware and Surgical Support businesses.
Inogen (INGN) Q2 Earnings and Revenues Beat Estimates
01:33pm, Monday, 08'th Aug 2022 Zacks Investment Research
Inogen's (INGN) second-quarter results benefit from higher revenues in its international business-to-business sales channel.
Allscripts (MDRX) Q2 Earnings & Revenues Surpass Estimates
01:31pm, Monday, 08'th Aug 2022 Zacks Investment Research
Allscripts' (MDRX) robust Q2 results demonstrate strength in both segments.
Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark
01:09pm, Monday, 08'th Aug 2022 Zacks Investment Research
According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.
Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised
04:58pm, Friday, 05'th Aug 2022 Zacks Investment Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.
QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View
04:57pm, Friday, 05'th Aug 2022 Zacks Investment Research
QuidelOrtho's (QDEL) robust performance across majority of its business units and geographies drives its second-quarter 2022 top line.
AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates
04:56pm, Friday, 05'th Aug 2022 Zacks Investment Research
AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.
Myriad Genetics (MYGN) Q2 Earnings Top, Gross Margin Down
04:01pm, Friday, 05'th Aug 2022 Zacks Investment Research
Myriad Genetics (MYGN) posts better-than-expected results in Q2 with contributions from most product lines.
Globus Medical (GMED) Q2 Earnings Beat, Gross Margin Dips
01:40pm, Friday, 05'th Aug 2022 Zacks Investment Research
Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.
Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View
05:37pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Syneos Health (SYNH) posts better-than-expected earnings in the second quarter and robust results across the Clinical Solutions and Commercial Solutions businesses.
Bruker (BRKR) Q2 Earnings Match Estimates, '22 Sales View Down
05:32pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Robust performance across the BSI and BEST segments drove Bruker's (BRKR) second-quarter top line.
PacBio's (PACB) Q2 Earnings Match Estimates, Revenues Lag
04:30pm, Thursday, 04'th Aug 2022 Zacks Investment Research
PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.
BD (BDX) Beats on Q3 Earnings and Revenues, Raises FY22 View
04:28pm, Thursday, 04'th Aug 2022 Zacks Investment Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal third quarter.
Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down
04:25pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
